Drug Profile


Alternative Names: HOE-239

Latest Information Update: 06 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hoechst Pharma
  • Developer Drugs for Neglected Diseases Initiative Foundation; Sanofi
  • Class Antiparasitics; Nitroimidazoles
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Trypanosomiasis
  • Phase II Chagas disease; Visceral leishmaniasis

Most Recent Events

  • 31 Jan 2018 Preregistration for Trypanosomiasis in European Union under Article 58 (PO)
  • 04 Nov 2017 Sanofi announces intention to submit regulatory application to EMA for Trypanosomiasis
  • 04 Nov 2017 Efficacy data from three phase II/III trials in Trypanosomiasis released by Drugs for Neglected Diseases Initiative Foundation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top